Loading…
Autologous hematopoietic stem cell transplantation improves survival outcomes in peripheral T-cell lymphomas: a multicenter retrospective real-world study
The aim of this study is to evaluate the survival benefit of consolidative autologous hematopoietic stem cell transplantation (ASCT) in patients with peripheral T-cell lymphomas (PTCL). In this retrospective study, the ASCT group underwent consolidative ASCT after first-line therapy at 14 transplant...
Saved in:
| Published in: | Annals of hematology 2023-11, Vol.102 (11), p.3185-3193 |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | |
|---|---|
| cites | cdi_FETCH-LOGICAL-c426t-8e1ebf044e3904998303bec71a2a77351c793b34ff949d6999db5369fa8067c03 |
| container_end_page | 3193 |
| container_issue | 11 |
| container_start_page | 3185 |
| container_title | Annals of hematology |
| container_volume | 102 |
| creator | Wu, Meng Wang, Fengrong Zhao, Shihua Li, Yajun Huang, Wenrong Nie, Bo Liu, Haisheng Liu, Xiaoqian Li, Wei Yu, Haifeng Yi, Kun Dong, Fei Dong, Yujun Yuan, Chenglu Ran, Xuehong Xiao, Xiubin Liu, Weiping Zhu, Jun |
| description | The aim of this study is to evaluate the survival benefit of consolidative autologous hematopoietic stem cell transplantation (ASCT) in patients with peripheral T-cell lymphomas (PTCL). In this retrospective study, the ASCT group underwent consolidative ASCT after first-line therapy at 14 transplantation centers in China between January 2001 and December 2019. Data were collected over the same time frame for the non-ASCT group from the database of lymphoma patient records at Peking University Cancer Hospital & Institute. A total of 120 and 317 patients were enrolled in the ASCT and non-ASCT groups, respectively, and their median ages were 43 years and 51 years, respectively. In the ASCT group, 101 patients had achieved complete remission (CR) and 19 patients had achieved partial remission at the time of ASCT. The median follow-up time was 40.2 months and 68 months, and the 3-year overall survival (OS) rate was 80.6% and 48.9% (
p
|
| doi_str_mv | 10.1007/s00277-023-05416-x |
| format | article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10567887</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2875636664</sourcerecordid><originalsourceid>FETCH-LOGICAL-c426t-8e1ebf044e3904998303bec71a2a77351c793b34ff949d6999db5369fa8067c03</originalsourceid><addsrcrecordid>eNp9UU1v1DAQjRCILoU_wAFZ4sIl4K_YMRdUVS0gVeJSzpaTTHZd2XGwndD9K_xavN1SPg74Ys3Mmzdv5lXVS4LfEozlu4QxlbLGlNW44UTUt4-qDeGMlrDlj6sNVkzVTXkn1bOUbjAmtOX0aXXCpCyB4pvqx9mSgwvbsCS0A29ymIOFbHuUMnjUg3MoRzOl2Zkpm2zDhKyfY1ghobTE1a7GobDkPviSsROaIdp5B7Gkr-u7frf38y54k94jg_ziCjtMGSKKkGNIM_TZrlAi4-rvIbqhzF6G_fPqyWhcghf3_2n19fLi-vxTffXl4-fzs6u651TkugUC3Yg5B6YwV6plmHXQS2KokZI1pJeKdYyPo-JqEEqpoWuYUKNpsZA9ZqfVhyPvvHQehoO2Il7P0XoT9zoYq_-uTHant2HVBDdCtq0sDG_uGWL4tkDK2tt0WN1MUA6raSu4IFLStkBf_wO9CUucyn4FJRvBhBC8oOgR1Zf7pAjjgxqC9cF7ffReF-_1nff6tjS9-nOPh5ZfZhcAOwJSKU1biL9n_4f2J1-Zv_Y</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2875636664</pqid></control><display><type>article</type><title>Autologous hematopoietic stem cell transplantation improves survival outcomes in peripheral T-cell lymphomas: a multicenter retrospective real-world study</title><source>Springer Link</source><creator>Wu, Meng ; Wang, Fengrong ; Zhao, Shihua ; Li, Yajun ; Huang, Wenrong ; Nie, Bo ; Liu, Haisheng ; Liu, Xiaoqian ; Li, Wei ; Yu, Haifeng ; Yi, Kun ; Dong, Fei ; Dong, Yujun ; Yuan, Chenglu ; Ran, Xuehong ; Xiao, Xiubin ; Liu, Weiping ; Zhu, Jun</creator><creatorcontrib>Wu, Meng ; Wang, Fengrong ; Zhao, Shihua ; Li, Yajun ; Huang, Wenrong ; Nie, Bo ; Liu, Haisheng ; Liu, Xiaoqian ; Li, Wei ; Yu, Haifeng ; Yi, Kun ; Dong, Fei ; Dong, Yujun ; Yuan, Chenglu ; Ran, Xuehong ; Xiao, Xiubin ; Liu, Weiping ; Zhu, Jun</creatorcontrib><description>The aim of this study is to evaluate the survival benefit of consolidative autologous hematopoietic stem cell transplantation (ASCT) in patients with peripheral T-cell lymphomas (PTCL). In this retrospective study, the ASCT group underwent consolidative ASCT after first-line therapy at 14 transplantation centers in China between January 2001 and December 2019. Data were collected over the same time frame for the non-ASCT group from the database of lymphoma patient records at Peking University Cancer Hospital & Institute. A total of 120 and 317 patients were enrolled in the ASCT and non-ASCT groups, respectively, and their median ages were 43 years and 51 years, respectively. In the ASCT group, 101 patients had achieved complete remission (CR) and 19 patients had achieved partial remission at the time of ASCT. The median follow-up time was 40.2 months and 68 months, and the 3-year overall survival (OS) rate was 80.6% and 48.9% (
p
< 0.001) for the ASCT and non-ASCT groups, respectively. The beneficial effect of ASCT for OS remained even after propensity score-matched (PSM) analysis (81.6% vs 68.3%,
p
= 0.001). Among the 203 patients who were aged ≤ 65 years and achieved CR, ASCT conferred a significant survival benefit (3-year progression-free survival [PFS]: 67.4% vs 47.0%,
p
= 0.004; 3-year OS: 84.0% vs 74.1%,
p
= 0.010), and this was also maintained after PSM analysis (3-year PFS: 66.6% vs 48.4%,
p
= 0.042; 3-year OS: 84.8% vs 70.5%,
p
= 0.011). Consolidative ASCT improved the survival outcome of PTCL patients, even those who achieved CR after first-line therapy.</description><identifier>ISSN: 0939-5555</identifier><identifier>ISSN: 1432-0584</identifier><identifier>EISSN: 1432-0584</identifier><identifier>DOI: 10.1007/s00277-023-05416-x</identifier><identifier>PMID: 37700194</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Adult ; Aged ; China - epidemiology ; Female ; Follow-Up Studies ; Hematology ; Hematopoietic Stem Cell Transplantation ; Humans ; Lymphoma ; Lymphoma, T-Cell, Peripheral - mortality ; Lymphoma, T-Cell, Peripheral - therapy ; Male ; Medicine ; Medicine & Public Health ; Middle Aged ; Oncology ; Original ; Original Article ; Remission Induction ; Retrospective Studies ; Stem cell transplantation ; Survival Rate ; Transplantation, Autologous ; Treatment Outcome ; Young Adult</subject><ispartof>Annals of hematology, 2023-11, Vol.102 (11), p.3185-3193</ispartof><rights>The Author(s) 2023</rights><rights>2023. The Author(s).</rights><rights>The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c426t-8e1ebf044e3904998303bec71a2a77351c793b34ff949d6999db5369fa8067c03</cites><orcidid>0000-0003-3479-2547</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37700194$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wu, Meng</creatorcontrib><creatorcontrib>Wang, Fengrong</creatorcontrib><creatorcontrib>Zhao, Shihua</creatorcontrib><creatorcontrib>Li, Yajun</creatorcontrib><creatorcontrib>Huang, Wenrong</creatorcontrib><creatorcontrib>Nie, Bo</creatorcontrib><creatorcontrib>Liu, Haisheng</creatorcontrib><creatorcontrib>Liu, Xiaoqian</creatorcontrib><creatorcontrib>Li, Wei</creatorcontrib><creatorcontrib>Yu, Haifeng</creatorcontrib><creatorcontrib>Yi, Kun</creatorcontrib><creatorcontrib>Dong, Fei</creatorcontrib><creatorcontrib>Dong, Yujun</creatorcontrib><creatorcontrib>Yuan, Chenglu</creatorcontrib><creatorcontrib>Ran, Xuehong</creatorcontrib><creatorcontrib>Xiao, Xiubin</creatorcontrib><creatorcontrib>Liu, Weiping</creatorcontrib><creatorcontrib>Zhu, Jun</creatorcontrib><title>Autologous hematopoietic stem cell transplantation improves survival outcomes in peripheral T-cell lymphomas: a multicenter retrospective real-world study</title><title>Annals of hematology</title><addtitle>Ann Hematol</addtitle><addtitle>Ann Hematol</addtitle><description>The aim of this study is to evaluate the survival benefit of consolidative autologous hematopoietic stem cell transplantation (ASCT) in patients with peripheral T-cell lymphomas (PTCL). In this retrospective study, the ASCT group underwent consolidative ASCT after first-line therapy at 14 transplantation centers in China between January 2001 and December 2019. Data were collected over the same time frame for the non-ASCT group from the database of lymphoma patient records at Peking University Cancer Hospital & Institute. A total of 120 and 317 patients were enrolled in the ASCT and non-ASCT groups, respectively, and their median ages were 43 years and 51 years, respectively. In the ASCT group, 101 patients had achieved complete remission (CR) and 19 patients had achieved partial remission at the time of ASCT. The median follow-up time was 40.2 months and 68 months, and the 3-year overall survival (OS) rate was 80.6% and 48.9% (
p
< 0.001) for the ASCT and non-ASCT groups, respectively. The beneficial effect of ASCT for OS remained even after propensity score-matched (PSM) analysis (81.6% vs 68.3%,
p
= 0.001). Among the 203 patients who were aged ≤ 65 years and achieved CR, ASCT conferred a significant survival benefit (3-year progression-free survival [PFS]: 67.4% vs 47.0%,
p
= 0.004; 3-year OS: 84.0% vs 74.1%,
p
= 0.010), and this was also maintained after PSM analysis (3-year PFS: 66.6% vs 48.4%,
p
= 0.042; 3-year OS: 84.8% vs 70.5%,
p
= 0.011). Consolidative ASCT improved the survival outcome of PTCL patients, even those who achieved CR after first-line therapy.</description><subject>Adult</subject><subject>Aged</subject><subject>China - epidemiology</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Hematology</subject><subject>Hematopoietic Stem Cell Transplantation</subject><subject>Humans</subject><subject>Lymphoma</subject><subject>Lymphoma, T-Cell, Peripheral - mortality</subject><subject>Lymphoma, T-Cell, Peripheral - therapy</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Oncology</subject><subject>Original</subject><subject>Original Article</subject><subject>Remission Induction</subject><subject>Retrospective Studies</subject><subject>Stem cell transplantation</subject><subject>Survival Rate</subject><subject>Transplantation, Autologous</subject><subject>Treatment Outcome</subject><subject>Young Adult</subject><issn>0939-5555</issn><issn>1432-0584</issn><issn>1432-0584</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNp9UU1v1DAQjRCILoU_wAFZ4sIl4K_YMRdUVS0gVeJSzpaTTHZd2XGwndD9K_xavN1SPg74Ys3Mmzdv5lXVS4LfEozlu4QxlbLGlNW44UTUt4-qDeGMlrDlj6sNVkzVTXkn1bOUbjAmtOX0aXXCpCyB4pvqx9mSgwvbsCS0A29ymIOFbHuUMnjUg3MoRzOl2Zkpm2zDhKyfY1ghobTE1a7GobDkPviSsROaIdp5B7Gkr-u7frf38y54k94jg_ziCjtMGSKKkGNIM_TZrlAi4-rvIbqhzF6G_fPqyWhcghf3_2n19fLi-vxTffXl4-fzs6u651TkugUC3Yg5B6YwV6plmHXQS2KokZI1pJeKdYyPo-JqEEqpoWuYUKNpsZA9ZqfVhyPvvHQehoO2Il7P0XoT9zoYq_-uTHant2HVBDdCtq0sDG_uGWL4tkDK2tt0WN1MUA6raSu4IFLStkBf_wO9CUucyn4FJRvBhBC8oOgR1Zf7pAjjgxqC9cF7ffReF-_1nff6tjS9-nOPh5ZfZhcAOwJSKU1biL9n_4f2J1-Zv_Y</recordid><startdate>20231101</startdate><enddate>20231101</enddate><creator>Wu, Meng</creator><creator>Wang, Fengrong</creator><creator>Zhao, Shihua</creator><creator>Li, Yajun</creator><creator>Huang, Wenrong</creator><creator>Nie, Bo</creator><creator>Liu, Haisheng</creator><creator>Liu, Xiaoqian</creator><creator>Li, Wei</creator><creator>Yu, Haifeng</creator><creator>Yi, Kun</creator><creator>Dong, Fei</creator><creator>Dong, Yujun</creator><creator>Yuan, Chenglu</creator><creator>Ran, Xuehong</creator><creator>Xiao, Xiubin</creator><creator>Liu, Weiping</creator><creator>Zhu, Jun</creator><general>Springer Berlin Heidelberg</general><general>Springer Nature B.V</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-3479-2547</orcidid></search><sort><creationdate>20231101</creationdate><title>Autologous hematopoietic stem cell transplantation improves survival outcomes in peripheral T-cell lymphomas: a multicenter retrospective real-world study</title><author>Wu, Meng ; Wang, Fengrong ; Zhao, Shihua ; Li, Yajun ; Huang, Wenrong ; Nie, Bo ; Liu, Haisheng ; Liu, Xiaoqian ; Li, Wei ; Yu, Haifeng ; Yi, Kun ; Dong, Fei ; Dong, Yujun ; Yuan, Chenglu ; Ran, Xuehong ; Xiao, Xiubin ; Liu, Weiping ; Zhu, Jun</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c426t-8e1ebf044e3904998303bec71a2a77351c793b34ff949d6999db5369fa8067c03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Adult</topic><topic>Aged</topic><topic>China - epidemiology</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Hematology</topic><topic>Hematopoietic Stem Cell Transplantation</topic><topic>Humans</topic><topic>Lymphoma</topic><topic>Lymphoma, T-Cell, Peripheral - mortality</topic><topic>Lymphoma, T-Cell, Peripheral - therapy</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Oncology</topic><topic>Original</topic><topic>Original Article</topic><topic>Remission Induction</topic><topic>Retrospective Studies</topic><topic>Stem cell transplantation</topic><topic>Survival Rate</topic><topic>Transplantation, Autologous</topic><topic>Treatment Outcome</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wu, Meng</creatorcontrib><creatorcontrib>Wang, Fengrong</creatorcontrib><creatorcontrib>Zhao, Shihua</creatorcontrib><creatorcontrib>Li, Yajun</creatorcontrib><creatorcontrib>Huang, Wenrong</creatorcontrib><creatorcontrib>Nie, Bo</creatorcontrib><creatorcontrib>Liu, Haisheng</creatorcontrib><creatorcontrib>Liu, Xiaoqian</creatorcontrib><creatorcontrib>Li, Wei</creatorcontrib><creatorcontrib>Yu, Haifeng</creatorcontrib><creatorcontrib>Yi, Kun</creatorcontrib><creatorcontrib>Dong, Fei</creatorcontrib><creatorcontrib>Dong, Yujun</creatorcontrib><creatorcontrib>Yuan, Chenglu</creatorcontrib><creatorcontrib>Ran, Xuehong</creatorcontrib><creatorcontrib>Xiao, Xiubin</creatorcontrib><creatorcontrib>Liu, Weiping</creatorcontrib><creatorcontrib>Zhu, Jun</creatorcontrib><collection>SpringerOpen</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Nursing & Allied Health Database</collection><collection>Health Medical collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Annals of hematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wu, Meng</au><au>Wang, Fengrong</au><au>Zhao, Shihua</au><au>Li, Yajun</au><au>Huang, Wenrong</au><au>Nie, Bo</au><au>Liu, Haisheng</au><au>Liu, Xiaoqian</au><au>Li, Wei</au><au>Yu, Haifeng</au><au>Yi, Kun</au><au>Dong, Fei</au><au>Dong, Yujun</au><au>Yuan, Chenglu</au><au>Ran, Xuehong</au><au>Xiao, Xiubin</au><au>Liu, Weiping</au><au>Zhu, Jun</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Autologous hematopoietic stem cell transplantation improves survival outcomes in peripheral T-cell lymphomas: a multicenter retrospective real-world study</atitle><jtitle>Annals of hematology</jtitle><stitle>Ann Hematol</stitle><addtitle>Ann Hematol</addtitle><date>2023-11-01</date><risdate>2023</risdate><volume>102</volume><issue>11</issue><spage>3185</spage><epage>3193</epage><pages>3185-3193</pages><issn>0939-5555</issn><issn>1432-0584</issn><eissn>1432-0584</eissn><abstract>The aim of this study is to evaluate the survival benefit of consolidative autologous hematopoietic stem cell transplantation (ASCT) in patients with peripheral T-cell lymphomas (PTCL). In this retrospective study, the ASCT group underwent consolidative ASCT after first-line therapy at 14 transplantation centers in China between January 2001 and December 2019. Data were collected over the same time frame for the non-ASCT group from the database of lymphoma patient records at Peking University Cancer Hospital & Institute. A total of 120 and 317 patients were enrolled in the ASCT and non-ASCT groups, respectively, and their median ages were 43 years and 51 years, respectively. In the ASCT group, 101 patients had achieved complete remission (CR) and 19 patients had achieved partial remission at the time of ASCT. The median follow-up time was 40.2 months and 68 months, and the 3-year overall survival (OS) rate was 80.6% and 48.9% (
p
< 0.001) for the ASCT and non-ASCT groups, respectively. The beneficial effect of ASCT for OS remained even after propensity score-matched (PSM) analysis (81.6% vs 68.3%,
p
= 0.001). Among the 203 patients who were aged ≤ 65 years and achieved CR, ASCT conferred a significant survival benefit (3-year progression-free survival [PFS]: 67.4% vs 47.0%,
p
= 0.004; 3-year OS: 84.0% vs 74.1%,
p
= 0.010), and this was also maintained after PSM analysis (3-year PFS: 66.6% vs 48.4%,
p
= 0.042; 3-year OS: 84.8% vs 70.5%,
p
= 0.011). Consolidative ASCT improved the survival outcome of PTCL patients, even those who achieved CR after first-line therapy.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>37700194</pmid><doi>10.1007/s00277-023-05416-x</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0003-3479-2547</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0939-5555 |
| ispartof | Annals of hematology, 2023-11, Vol.102 (11), p.3185-3193 |
| issn | 0939-5555 1432-0584 1432-0584 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10567887 |
| source | Springer Link |
| subjects | Adult Aged China - epidemiology Female Follow-Up Studies Hematology Hematopoietic Stem Cell Transplantation Humans Lymphoma Lymphoma, T-Cell, Peripheral - mortality Lymphoma, T-Cell, Peripheral - therapy Male Medicine Medicine & Public Health Middle Aged Oncology Original Original Article Remission Induction Retrospective Studies Stem cell transplantation Survival Rate Transplantation, Autologous Treatment Outcome Young Adult |
| title | Autologous hematopoietic stem cell transplantation improves survival outcomes in peripheral T-cell lymphomas: a multicenter retrospective real-world study |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T22%3A53%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Autologous%20hematopoietic%20stem%20cell%20transplantation%20improves%20survival%20outcomes%20in%20peripheral%20T-cell%20lymphomas:%20a%20multicenter%20retrospective%20real-world%20study&rft.jtitle=Annals%20of%20hematology&rft.au=Wu,%20Meng&rft.date=2023-11-01&rft.volume=102&rft.issue=11&rft.spage=3185&rft.epage=3193&rft.pages=3185-3193&rft.issn=0939-5555&rft.eissn=1432-0584&rft_id=info:doi/10.1007/s00277-023-05416-x&rft_dat=%3Cproquest_pubme%3E2875636664%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c426t-8e1ebf044e3904998303bec71a2a77351c793b34ff949d6999db5369fa8067c03%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2875636664&rft_id=info:pmid/37700194&rfr_iscdi=true |